Современные аспекты лечения урогенитальной атрофии (по итогам консенсуса Британского общества менопаузы)
- Авторы: Балан В.Е1, Тихомирова Е.В1, Царькова А.В1, Гаджиева З.К2
-
Учреждения:
- ГБУЗ МО «Московский областной научно-исследовательский институт акушерства и гинекологии
- ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский университет)
- Выпуск: № 5 (2019)
- Страницы: 150-154
- Раздел: Статьи
- URL: https://journals.eco-vector.com/1728-2985/article/view/312327
- DOI: https://doi.org/10.18565/urology.2019.5.150-154
- ID: 312327
Цитировать
Полный текст
![Открытый доступ](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Аннотация
Полный текст
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Об авторах
В. Е Балан
ГБУЗ МО «Московский областной научно-исследовательский институт акушерства и гинекологии
Email: balanmed@gmail.com
д.м.н., профессор, руководитель поликлинического отделения
Е. В Тихомирова
ГБУЗ МО «Московский областной научно-исследовательский институт акушерства и гинекологии
Email: heltik03@gmail.com
к.м.н., старший научный сотрудник поликлинического отделения
А. В Царькова
ГБУЗ МО «Московский областной научно-исследовательский институт акушерства и гинекологии
Email: heltik03@gmail.com
к.м.н., старший научный сотрудник поликлинического отделения
З. К Гаджиева
ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский университет)
Email: alinka-lapina@mail.ru
младший научный сотрудник поликлинического отделения
Список литературы
- Балан В.Е. Урогенитальные расстройства и климактерии (клиника, диагностика, заместительная гормонотерапия). Дисс. докт. мед. наук. М., 1998
- Гаджиева З.К. Функциональное состояние нижних мочевых путей и медикаментозная коррекция нарушений мочеиспускания у женщин в климактерии. Дисс. канд. мед. наук. М., 2001
- Тихомирова Е.В. Особенности клиники и лечения урогенитальных расстройств в перименопаузе. Дисс. канд. мед. наук. М., 2005
- Амирова Ж.С. Оптимизация диагностики и лечения гиперактивного мочевого пузыря у женщин с урогенитальными расстройствами в климактерии. Дисс. канд. мед. наук. 152 с.
- Levine K.B., Williams R.E., Hartmann K.E. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause. 2008; 15: 661-666.
- Sarrel P.M. Effects of hormone replacement therapy on sexual psychophysiology and behavior in postmenopause. J. Womens Health Gend Based Med 2000; 9: S25-S32. Review. Erratum in: J. Womens Health Gend Based Med. 2001; 10: 91.
- Dennerstein L., Randolph J., Taffe J., et al. Hormones, mood, sexuality, and the menopausal transition. FertilSteril. 2002; 77: S42-S48.
- Banks J., Batty G.D., Nazroo J., and Steptoe A. The dynamics of ageing: evidence from the English Longitudinal Study of Ageing. 2002-2015 (Wave 7). ESRC & IFS: London, 2016.
- Samsioe G., Jansson I., Mellstro€m D., et al. Occurrence, nature and treatment of urinary incontinence in a 70- year-old female population. Maturitas. 1985; 7: 335-342.
- Van Geelen J.M., van de Weijer P.H., Arnolds H.T. Urogenital symptoms and resulting discomfort in non- institutionalized Dutch women aged 50-75 years. IntUrogynecol J. Pelvic Floor Dysfunct. 2000; 11: 9-14.
- Davila G.W., Singh A., Karapanagiotou I., et al. Are women with urogenital atrophy symptomatic? Am J. ObstetGynecol. 2003; 188: 382-388.
- Notelovitz M., Funk S., Nanavati N., et al. Estradiol absorption from vaginal tablets in postmenopausal women. ObstetGynecol. 2002; 99: 556-562.
- Sturdee D.W., Panay N. International Menopause Society Writing Group. Recommendations for the management of post-menopausal vaginal atrophy. Climacteric. 2010; 13: 509-522.
- Portman D.J., Gass M.L.,S., Kingsberg S., et al. Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy from the international society for the study of women’s sexual health and the North American Menopause Society Menopause. J. North Am Menopause Soc. 2014; 21: 1063-1068.
- Blakeman P.J., Hilton P., Bulmer J.N. Oestrogen and progesterone receptor expression in the female lower urinary tract, with reference to oestrogen status. BJU Int. 2000; 86: 32-38.
- Smith P. Estrogens and the urogenital tract. Studies on steroid hormone receptors and a clinical study on a new estradiolreleasing vaginal ring. Acta Obstet Gynecol Scand Suppl. 1993; 157: 1-26.
- Zhu L., Lang J.H., Feng R.E., et al. Study one strogen receptor around levatorani muscle for female stress urinary incontinence. Zhonghua Fu Chan KeZaZhi 2004; 39: 655-657.
- Sarrel P.M. Sexuality and menopause. ObstetGynecol. 1990; 75: 26S-30S.
- Bachmann G.A., Leiblum S.R. The impact of hor- mones on menopausal sexuality: a literature review. Menopause. 2004; 11: 120-130.
- Laan E., Everaerd W. and Evers A. Assessment of female sexual arousal: response specificity and construct validity. Psychophysiology. 1995; 32: 476-485.
- Bygdeman M., Swahn M.L. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996; 23: 259-263.
- Biglia N., Peano E., Sgandurra P., et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol. 2010; 26: 404-412.
- Edwards D., Panay N. Treating vulvovaginal atrophy/ genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. 2016; 19: 151-161.
- Rosen A.D, Rosen T. Study of condom integrity after brief exposure to over the counter vaginal preparations. South Med J. 1999; 92: 305-307.
- NICE Menopause guideline: diagnosis and management [NG23]. November 2015.
- Suckling J., Lethaby A., Kennedy R Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006; (4): CD001500. Review. Update in: Cochrane Database Syst Rev 2016; 8: CD001500. PubMed PMID: 17054136.
- Al-Baghdadi O., Ewies A.A. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric. 2009; 12: 91-105.
- Ulrich L.S., Naessen T., Elia D., et al. VAG-1748 trial investigators. Endometrial safety of ultra-low- dose Vagifem 10 microg in postmenopausal women with vaginal atrophy. Climacteric. 2010; 13: 228-237.
- Haspels A.A., Luisi M., Kicovic P.M. Endocrinological and clinical investigations in post-menopausal women following administration of vaginal cream containing oestriol. Maturitas. 1981;3:321-327.
- Constantine G.D., Simon J.A., Pickar J.H., et al. REJOICE Study Group. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy. Menopause. 2017; 24: 409-416.
- Cardozo L, Bachmann G, McClish D, et al. Metaanalysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1998; 92: 722-727.
- Cardozo L., Lose G., McClish D., et al. A systematic review of estrogens for recurrent urinary tract infections: third report of the hormones and urogenital therapy (HUT) committee. Int Urogynecol J Pelvic Floor Dysfunct. 2001; 12: 15-20.
- Cardozo L., Lose G., McClish D., et al. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand. 2004; 83: 892-897.
- Sant M., Galea P, Brincat M.P. A comparative study between oestrogen replacement therapy, anticholinergic treatment and a combination of both in the management of detrusor instability in postmenopausal women. In: Book of Abstracts, The 10th World Congress on the menopause, Berlin 2002.
- NICE Urinary incontinence in women: management clinical guideline nice.org.uk/guidance/cg171 (2015).
- Fantl J.A., Cardozo L., McClish D.K. Estrogen therapy in the management of urinary incontinence in postmen- opausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1994; 83(1): 12-18.
- Henalla SM, Hutchins CJ, Robinson P, et al. Non-operative methods in the treatment of female genuine stress incontinence of urine. J Obstet Gynaecol. 2009; 9: 222-225.
- Nappi R.E., Kokot-Kierepa M. Vaginal health: insights, views & attitudes (VIVA) - results from an international survey. Climacteric. 2012; 15: 36-44.
- Woyka J., Tanna N., Abernthy K., et al. A menopause service for women with breast cancer or at high risk from breast cancer. EJSO. 2009; 35: 1226-1227.
- Portman D., Palacios S., Nappi R.E., et al. Ospemifene, a non- oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal. vulvar and vaginal atrophy: a randomised, placebo- controlled, phase III trial. Maturitas. 2014; 78: 91-98.
- Constantine G., Graham S., Portman D.J., et al. Female sexual function improved with ospemifene in post- menopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric. 2015; 18: 226-232.
- Cui Y., Zong H., Yan H., et al. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis. J Sex Med. 2014; 11: 487-497.
- Salvatore S., Pitsouni E., Del Deo, et al. Sexual function in women suffering from genitourinary syndrome of menopause treated with fractionated CO(2) laser. Sex Med Rev. 2017; 5: 486-494.
- Gambacciani M., Levancini M., Russo E., et al. Long-term effects of vaginal erbium laser in the treatment of genitourinary syndrome of menopause. Climacteric. 2018; 21: 148-152.
- Mikic A.N., et al. 415 Use of vaginal erbium laser in treat- ment of vaginal relaxation syndrome and pelvic floor dysfunction. JISM 2017; 14: S126-S127.
- Labrie F., Archer D.F., Koltun W., et al. Efficacy of intra- vaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016; 23: 243-256.
- Labrie F., Archer D.F., Bouchard C., et al. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas. 2015; 81(1): 46-56.
- Mario Preti; Pedro Vieira-Baptista; Giuseppe Digesu; Carol Bretschneider;MargotDamaser; OktayDemirkesen; Debra Heller; NasideMangir; Claudia Marchitelli The Clinical Role of LASER for Vulvar and Vaginal Treatments in Gynecology and Female Urology: An ICS/ISSVD Best Practice Consensus DocumentJournal of Lower Genital Tract Disease. 23(2):151-160, APRIL 2019.
- BMS - Consensus statement Joan Pitkin; on behalf of the British Menopause Society medical advisory council Post Reproductive Health. 2018; 24(3):133-138.
Дополнительные файлы
![](/img/style/loading.gif)